N/A N=9 Transcranial Magnetic Stimulation for Facial Pain
Trigeminal Nerve Injuries · Post-herpetic Neuralgia · Facial Pain
Primary: Visual Analogue Scale (VAS) — 5.4 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=17 Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)
Hypogonadotropic Hypogonadism
Primary: Change From Baseline in Log-Transformed Testicular Volume (TV) to Week 64 — 1.5; 14.5 mL
Phase 3 N=336 Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Macular Degeneration
Primary: Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) Letter Score for the Study Eye — -0.3; -0.5 Letters read correctly…
Phase 3 N=258 To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma
Follicular Lymphoma
Primary: Primary Efficacy Endpoint - Overall Response Rate by 7 Months — 108; 104 Participants
Phase 2 N=163 CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Advanced Hepatocellular Carcinoma · Liver Cancer · Hepatic Cancer
Primary: Time to Progression (TTP) Following CS1008 in Combination With Sorafenib Compared to Sorafenib Alone in Participants With Advanced Liver Cancer — 2.8; 3.0; 3.9 months
N/A N=98 Effectiveness of Contingency Management in the Treatment of Crack Addiction in Brazil
Substance Use Disorders · Contingency Management · Addiction, Cocaine
Primary: Pattern of Crack Cocaine Use — 14.3; 40.7 percent of negative cocaine samples
Phase 2 N=70 Self Assembling Peptide P11-4 in Patients With Early Occlusal Carious Lesions
Dental Caries
Primary: Caries Activity and Progression Assessment Using LASER Fluorescence Readings by Diagnodent® Device. — 18.6; 1.1 units on a scale
Phase 3 N=393 Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients
Chronic Iron Overload
Primary: Percentage of Successfully Chelated Patients — 69; 80 Participants
Phase 3 N=100 Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease
Glycogen Storage Disease Type II;Pompe's Disease
Primary: PAP: Change From Baseline in Percent Predicted FVC in Upright Position at Week 49 — 2.89; 0.46 percent predicted FVC — p=0.0074
N/A N=73 Child Characteristics, Neuromarkers, and Intervention Components Impacting Treatment Outcome: CCT, TF-CBT, TAU
Stress Disorders, Post-Traumatic
Primary: Change From Baseline in UCLA Posttraumatic Stress Disorder (PTSD) Reaction Index for DSM 5 (Child Self-report) — -13.3; -17.8; -9.8 score on a scale
N/A N=243 VIVO Clinical Study
Symptomatic Venous Outflow Obstruction in the Iliofemoral Vein
Primary: Number of Participants With 30-day Freedom From Major Adverse Events — 232 Participants — p=<0.0001
N/A N=320 Wide Frequency Band Test of Hearing in Veterans
Hearing Loss, Sensorineural · Hearing Loss, Conductive · Hearing Loss, Mixed Conductive-Sensorineural
Primary: Experimental Middle Ear Test: Ambient Wideband Absorbance — 0.39; 0.38; 0.32 Ratio
Phase 4 N=22 A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in Residual Volume (RV) at 6 Hours Postdose — 0.004; -0.319 L — p=0.0987
N/A N=1,822 PARTNER II Trial: S3iCAP
Aortic Stenosis
Primary: Death — 12 Participants
N/A N=35 The Oxford Optimisation of PCI Study (OXOPT-PCI Study)
Coronary Artery Disease
Primary: Final Fractional Flow Reserve (FFR) After Intracoronary Stenting — 0.80; 0.84; 0.88 Ratio